<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010906</url>
  </required_header>
  <id_info>
    <org_study_id>7009-005</org_study_id>
    <secondary_id>2009_674</secondary_id>
    <nct_id>NCT01010906</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)</brief_title>
  <official_title>An Open-label, 3-Part, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-7009</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a 3-part study comparing the pharmacokinetics after administration of vaniprevir
      (MK-7009) for participants with mild, moderate or severe hepatic insufficiency with healthy
      matched control participants. The primary hypothesis is that the area under the curve (AUC)
      (0 to infinity) of vaniprevir for participants with mild, moderate, or severe hepatic
      insufficiency is similar to that observed in healthy matched controlled participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) (0-infinity) of Vaniprevir in Blood Plasma Following Single Dose Administration</measure>
    <time_frame>0-48 hours postdose</time_frame>
    <description>Participants were administered a single dose of vaniprevir; then their blood was collected at the following time points: 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32 and 48 hours postdose. The AUC (0-infinity) of vaniprevir in blood plasma was based on an analysis of covariance (ANCOVA) model used to analyze natural log-transformed values that were back-transformed to derive geometric least-squares mean and confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of Vaniprevir in Blood Plasma Following Single Dose Administration</measure>
    <time_frame>0-48 hours postdose</time_frame>
    <description>Participants were administered a single dose of vaniprevir; then their blood was collected at the following time points: 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32 and 48 hours postdose. The Cmax of vaniprevir in blood plasma was based on an ANCOVA model used to analyze natural log-transformed values that were back-transformed to derive geometric least-squares mean and confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Mild Hepatic Insufficiency (HI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control to Mild HI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, matched to mild HI, control participants administered a single 300 mg oral tablet of vaniprevir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate HI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control to Moderate HI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, matched to moderate HI, control participants administered a single 300 mg oral tablet of vaniprevir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe HI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe HI administered a single 200 mg oral tablet of vaniprevir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control to Severe HI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, matched to severe HI, control participants administered a single 200 mg oral tablet of vaniprevir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaniprevir 300 mg</intervention_name>
    <description>single dose administration of 300 mg oral tablet</description>
    <arm_group_label>Mild Hepatic Insufficiency (HI)</arm_group_label>
    <arm_group_label>Healthy Control to Mild HI</arm_group_label>
    <arm_group_label>Moderate HI</arm_group_label>
    <arm_group_label>Healthy Control to Moderate HI</arm_group_label>
    <other_name>MK-7009</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaniprevir 200 mg</intervention_name>
    <description>single dose administration of 200 mg oral tablet</description>
    <arm_group_label>Severe HI</arm_group_label>
    <arm_group_label>Healthy Control to Severe HI</arm_group_label>
    <other_name>MK-7009</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Hepatic Participants:

          -  Females of reproductive potential test negative for pregnancy and agree to use an
             appropriate method of contraception during the study

          -  Apart from hepatic insufficiency, is in good general health

          -  Has a diagnosis of chronic stable hepatic insufficiency

          -  Score on the Child-Pugh scale ranged from 5 to 6 (mild hepatic insufficiency); from 7
             to 9 (moderate hepatic insufficiency); from 10 to 15 (severe hepatic insufficiency).
             Moderate and Severe participants must have had a 50% score of 2 or higher on at least
             one of the laboratory parameters (i.e., albumin, prothrombin time, bilirubin) at the
             prestudy visit.

        Healthy Matched Participants:

          -  Females of reproductive potential test negative for pregnancy and agree to use an
             appropriate method of contraception during the study

          -  Is in good health

        Exclusion Criteria:

          -  Female is pregnant, lactating, expecting to become pregnant or donate eggs

          -  Has a history of stroke or seizures

          -  Has a history of cancer

          -  Is unable to refrain from the use of any prescription or non-prescription medication

          -  Consumes excessive amounts of alcohol or caffeinated beverages daily

          -  Has had surgery, donated blood or participated in another investigational study with
             in the last 4 weeks

          -  Is a regular user or past abuser of any illicit drug including alcohol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2009</study_first_submitted>
  <study_first_submitted_qc>November 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2009</study_first_posted>
  <results_first_submitted>September 26, 2014</results_first_submitted>
  <results_first_submitted_qc>September 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 29, 2014</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=7009-005&amp;kw=7009-005&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mild Hepatic Insufficiency (HI)</title>
          <description>Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="P2">
          <title>Healthy Control for Mild HI</title>
          <description>Healthy matched control participants administered a single 300 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="P3">
          <title>Moderate HI</title>
          <description>Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="P4">
          <title>Healthy Control for Moderate HI</title>
          <description>Healthy matched control participants administered a single 300 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="P5">
          <title>Severe HI</title>
          <description>Participants with severe HI administered a single 200 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="P6">
          <title>Healthy Control for Severe HI</title>
          <description>Healthy matched control participants administered a single 200 mg oral tablet of vaniprevir</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mild Hepatic Insufficiency (HI)</title>
          <description>Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="B2">
          <title>Healthy Control for Mild HI</title>
          <description>Healthy matched control participants administered a single 300 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="B3">
          <title>Moderate HI</title>
          <description>Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="B4">
          <title>Healthy Control for Moderate HI</title>
          <description>Healthy matched control participants administered a single 300 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="B5">
          <title>Severe HI</title>
          <description>Participants with severe HI administered a single 200 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="B6">
          <title>Healthy Control for Severe HI</title>
          <description>Healthy matched control participants administered a single 200 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="5.03"/>
                    <measurement group_id="B2" value="52.1" spread="3.54"/>
                    <measurement group_id="B3" value="52.1" spread="6.51"/>
                    <measurement group_id="B4" value="53.3" spread="4.90"/>
                    <measurement group_id="B5" value="53.4" spread="6.08"/>
                    <measurement group_id="B6" value="52.6" spread="7.04"/>
                    <measurement group_id="B7" value="52.3" spread="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) (0-infinity) of Vaniprevir in Blood Plasma Following Single Dose Administration</title>
        <description>Participants were administered a single dose of vaniprevir; then their blood was collected at the following time points: 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32 and 48 hours postdose. The AUC (0-infinity) of vaniprevir in blood plasma was based on an analysis of covariance (ANCOVA) model used to analyze natural log-transformed values that were back-transformed to derive geometric least-squares mean and confidence interval.</description>
        <time_frame>0-48 hours postdose</time_frame>
        <population>Participants administered at least one dose of investigational drug. AUC for one participant with Mild HI was not estimated due to poor correlation of the linear regression.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Hepatic Insufficiency (HI)</title>
            <description>Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control for Mild HI</title>
            <description>Healthy matched control participants administered a single 300 mg oral tablet of vaniprevir</description>
          </group>
          <group group_id="O3">
            <title>Moderate HI</title>
            <description>Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir</description>
          </group>
          <group group_id="O4">
            <title>Healthy Control for Moderate HI</title>
            <description>Healthy matched control participants administered a single 300 mg oral tablet of vaniprevir</description>
          </group>
          <group group_id="O5">
            <title>Severe HI</title>
            <description>Participants with severe HI administered a single 200 mg oral tablet of vaniprevir</description>
          </group>
          <group group_id="O6">
            <title>Healthy Control for Severe HI</title>
            <description>Healthy matched control participants administered a single 200 mg oral tablet of vaniprevir</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) (0-infinity) of Vaniprevir in Blood Plasma Following Single Dose Administration</title>
          <description>Participants were administered a single dose of vaniprevir; then their blood was collected at the following time points: 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32 and 48 hours postdose. The AUC (0-infinity) of vaniprevir in blood plasma was based on an analysis of covariance (ANCOVA) model used to analyze natural log-transformed values that were back-transformed to derive geometric least-squares mean and confidence interval.</description>
          <population>Participants administered at least one dose of investigational drug. AUC for one participant with Mild HI was not estimated due to poor correlation of the linear regression.</population>
          <units>µM.hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" lower_limit="1.39" upper_limit="5.18"/>
                    <measurement group_id="O2" value="1.48" lower_limit="0.84" upper_limit="2.59"/>
                    <measurement group_id="O3" value="5.09" lower_limit="2.21" upper_limit="11.70"/>
                    <measurement group_id="O4" value="1.64" lower_limit="0.67" upper_limit="3.98"/>
                    <measurement group_id="O5" value="7.79" lower_limit="5.03" upper_limit="12.00"/>
                    <measurement group_id="O6" value="0.925" lower_limit="0.61" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% Confidence Interval falls within the interval [0.50, 2.00], then treatment of HI participants is similar to treatment of healthy matched for mild HI participants.</non_inferiority_desc>
            <param_type>Geometric Least-Square Mean Ratio</param_type>
            <param_value>1.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>3.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% Confidence Interval falls within the interval [0.50, 2.00], then treatment of HI participants is similar to treatment of healthy matched for moderate HI participants.</non_inferiority_desc>
            <param_type>Geometric Least-Square Mean Ratio</param_type>
            <param_value>3.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.60</ci_lower_limit>
            <ci_upper_limit>6.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% Confidence Interval falls within the interval [0.50, 2.00], then treatment of HI participants is similar to treatment of healthy matched for severe HI participants.</non_inferiority_desc>
            <param_type>Geometric Least-Square Mean Ratio</param_type>
            <param_value>8.42</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.20</ci_lower_limit>
            <ci_upper_limit>13.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) of Vaniprevir in Blood Plasma Following Single Dose Administration</title>
        <description>Participants were administered a single dose of vaniprevir; then their blood was collected at the following time points: 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32 and 48 hours postdose. The Cmax of vaniprevir in blood plasma was based on an ANCOVA model used to analyze natural log-transformed values that were back-transformed to derive geometric least-squares mean and confidence interval.</description>
        <time_frame>0-48 hours postdose</time_frame>
        <population>Participants administered at least one dose of investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild Hepatic Insufficiency (HI)</title>
            <description>Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control for Mild HI</title>
            <description>Healthy matched control participants administered a single 300 mg oral tablet of vaniprevir</description>
          </group>
          <group group_id="O3">
            <title>Moderate HI</title>
            <description>Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir</description>
          </group>
          <group group_id="O4">
            <title>Healthy Control for Moderate HI</title>
            <description>Healthy matched control participants administered a single 300 mg oral tablet of vaniprevir</description>
          </group>
          <group group_id="O5">
            <title>Severe HI</title>
            <description>Participants with severe HI administered a single 200 mg oral tablet of vaniprevir</description>
          </group>
          <group group_id="O6">
            <title>Healthy Control for Severe HI</title>
            <description>Healthy matched control participants administered a single 200 mg oral tablet of vaniprevir</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Vaniprevir in Blood Plasma Following Single Dose Administration</title>
          <description>Participants were administered a single dose of vaniprevir; then their blood was collected at the following time points: 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32 and 48 hours postdose. The Cmax of vaniprevir in blood plasma was based on an ANCOVA model used to analyze natural log-transformed values that were back-transformed to derive geometric least-squares mean and confidence interval.</description>
          <population>Participants administered at least one dose of investigational drug.</population>
          <units>µM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.922" lower_limit="0.44" upper_limit="1.94"/>
                    <measurement group_id="O2" value="0.586" lower_limit="0.29" upper_limit="1.17"/>
                    <measurement group_id="O3" value="1.88" lower_limit="0.88" upper_limit="4.01"/>
                    <measurement group_id="O4" value="0.852" lower_limit="0.38" upper_limit="1.91"/>
                    <measurement group_id="O5" value="2.06" lower_limit="1.37" upper_limit="3.12"/>
                    <measurement group_id="O6" value="0.335" lower_limit="0.23" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least-Square Mean Ratio</param_type>
            <param_value>1.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least-Square Mean Ratio</param_type>
            <param_value>2.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>4.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least-Square Mean Ratio</param_type>
            <param_value>6.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.90</ci_lower_limit>
            <ci_upper_limit>9.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after administration of study drug</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mild Hepatic Insufficiency (HI)</title>
          <description>Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="E2">
          <title>Healthy Control for Mild HI</title>
          <description>Healthy matched control participants administered a single 300 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="E3">
          <title>Moderate HI</title>
          <description>Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="E4">
          <title>Healthy Control for Moderate HI</title>
          <description>Healthy matched control participants administered a single 300 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="E5">
          <title>Severe HI</title>
          <description>Participants with severe HI administered a single 200 mg oral tablet of vaniprevir</description>
        </group>
        <group group_id="E6">
          <title>Healthy Control for Severe HI</title>
          <description>Healthy matched control participants administered a single 200 mg oral tablet of vaniprevir</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersplenism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

